1st Quarter - Report — SEQIRUS for SEQIRUS (2026)

Firm

SEQIRUS

Client

SEQIRUS

Income

—

Expenses

$280,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY2026 and FY2027 Appropriations, policies related to pandemic preparedness, public health, and influenza preparedness; H.R. 3838/S. 2296, FY2026 NDAA, policies related to pandemic preparedness, public health, and influenza preparedness; FY2027 President's Budget, policies related to pandemic preparedness, public health, and influenza preparedness; CBER 2026 Guidance Agenda; funding for biodefense activities

Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.

Lobbyist	Covered position, as disclosed
CHRISTINE FARQUHARSON	—

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB)

Bills named: S. 2296 (119th), H.R. 3838 (119th)

Health Issues HCR

Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.

Lobbyist	Covered position, as disclosed
CHRISTINE FARQUHARSON	—

Contacted: Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3838 (119th), S. 2296 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.